A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis

Genes and Immunity

Volumn 13, Issue 1, 2012, Pages 21-28

  Vandenbroeck, K ^a,b   Alvarez, J ^c   Swaminathan, B ^a   Alloza, I ^a   Matesanz, F ^d   Urcelay, E ^e   Comabella, M ^f   Alcina, A ^d   Fedetz, M ^d   Ortiz, M A ^e   Izquierdo, G ^g   Fernandez, O ^h   Rodriguez Ezpeleta, N ^c   Matute, C ^a   Caillier, S ⁱ   Arroyo, R ^e   Montalban, X ^f   Oksenberg, J R ⁱ   Antiguedad A ^j   Aransay, A ^c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BASQUE FOUNDATION FOR SCIENCE   (Spain)

^c CIC BIOGUNE   (Spain)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HOSPITAL DE BASURTO   (Spain)

more..

Author keywords

cytokine; genetics; multiple sclerosis; single nucleotide polymorphismx; SOCS1

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 28; INTERLEUKIN 7 RECEPTOR; ONCOSTATIN M RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ALPHA CHAIN; ARTICLE; CHROMOSOME 16; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CHROMOSOMES, HUMAN, PAIR 16; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LECTINS, C-TYPE; MALE; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; YOUNG ADULT;

EID: 84855915179     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2011.44     Document Type: Article

References (37)

1. Oksenberg JR, Baranzini SE. Multiple sclerosis genetics-is the glass half full, or half empty? Nat Rev Neurol 2010; 6: 429-437.
2. The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Eng J Med 2007; 357: 851-862.
3. De Jager PL, Jia X, Wang J, de Bakker PIW, Ottoboni L, Aggarwal NT et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.
4. The International Multiple Sclerosis Genetics Consortium. IL12A, MPHOSPH9/CDK2AP1 and RSG1 are novel multiple sclerosis susceptibility loci. Genes Immun 2010; 11: 397-405.
5. Matute C, Domercq M, Sánchez-Gómez MV. Glutamatemediated glial injury: mechanisms and clinical importance. Glia 2006; 53: 212-224.
6. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallström E, Khademi M et al. Variation in interleukin 7 receptor a chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-1113. (Pubitemid 47340654)
7. O'Doherty C, Kantarci O, Vandenbroeck K. IL7RA polymorphisms and susceptibility to multiple sclerosis. N Eng J Med 2008; 358: 753-754. (Pubitemid 351240775)
8. The International Multiple Sclerosis Genetics Consortium. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 2009; 10: 11-14.
9. Berard JL, Kerr BJ, Johnson HM, David S. Differential expression of SOCS1 in macrophages in relapsing-remitting and chronic EAE and its role in disease severity. Glia 2010; 58: 1816-1826.
10. Vandenbroeck K. Cytokine Gene Polymorphisms in Multifactorial Conditions. CRC Press: Boca Raton, 2006.
11. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain 2005; 128: 1016-1025. (Pubitemid 40675457)
12. Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, Matthews PM et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 2010; 133: 2603-2611.
13. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344. (Pubitemid 351398518)
14. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M et al. Genome-wide scan of 500 000 singlenucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-978.
15. Baker BJ, Akhtar LN, Benveniste EN. SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol 2009; 30: 392-400.
16. Maier J, Kincaid C, Pagenstecher A, Campbell IL. Regulation of signal transducer and activator of transcription and suppressor of cytokine-signaling gene expression in the brain of mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune encephalomyelitis. Am J Pathol 2002; 160: 271-288. (Pubitemid 34052288)
17. Stark JL, Cross AH. Differential expression of suppressors of cytokine signaling-1 and-3 and related cytokines in central nervous system during remitting versus non-remitting forms of experimental autoimmune encephalomyelitis. Int Immunol 2006; 18: 347-353. (Pubitemid 43160147)
18. Balabanov R, Strand K, Goswami R, McMahon E, Begolka W, Miller SD et al. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci 2007; 27: 2013-2024.
19. Mujitaba MG, Flowers LO, Patel CB, Patel RA, Haider MI, Johnson HM. Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J Immunol 2005; 175: 5077-5086. (Pubitemid 41456391)
20. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol 2008; 180: 3746-3756.
21. Gylvin T, Ek J, Nolsøe R, Albrechtsen A, Andersen G, Bergholdt R et al. Functional SOCS1 polymorphisms are associated with variation in obesity in whites. Diabetes Obes Metab 2009; 11: 196-203.
22. Harada M, Nakahima K, Hirota T, Shimizu M, Doi S, Fujita K et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol 2007; 36: 491-496. (Pubitemid 46623008)
23. Zuvich RL, McCauleu JL, Oksenberg JTR, Sawcer SJ, De Jager PL, IMSGC et al. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010; 127: 525-535.
24. Wykes SM, Nelson JE, Visscher DW, Djakiew D, Krawetz SA. Coordinate expression of the PRM1, PRM2, and TNP2 multigene locus in human testis. DNA Cell Biol 1995; 14: 155-161.
25. Beyeen AD, Adzemovic MZ, Ockinger J, Stridh P, Becanovic K, Laaksonen H et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010; 185: 6883-6890.
26. Genetic Analysis of Psoriasis Consortium et al. A genomewide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985-990.
27. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. Am J Hum Genet 2007; 80: 531-538.
28. Clarke GM, Cardon LR. Aspects of observing and claiming allele flips in association studies. Genet Epidemiol 2010; 34: 266-274.
29. Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, Ingram G et al. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet 2009; 10: 1309-1313.
30. Vandenbroeck K, Alloza I, Swaminathan B, Antigüedad A, Otaegui D, Olascoaga J et al. Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes Immun 2011; 12: 40-45.
31. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008; 45: 362-369. (Pubitemid 351839477)
32. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231. (Pubitemid 13158528)
33. MacDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
34. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575. (Pubitemid 47330214)
35. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
36. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006; 38: 209-213. (Pubitemid 43177235)
37. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938-2939.